U.S. markets close in 11 minutes

T2 Biosystems, Inc. (TTOO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.3111-0.1689 (-6.81%)
As of 3:49PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Gap Down

Gap Down

Previous Close2.4800
Open2.5700
Bid2.2900 x 3200
Ask2.3000 x 3200
Day's Range2.2600 - 2.5800
52 Week Range0.2350 - 3.7900
Volume5,653,699
Avg. Volume11,968,062
Market Cap341.941M
Beta (5Y Monthly)0.47
PE Ratio (TTM)N/A
EPS (TTM)-0.5290
Earnings DateMar 04, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.18
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • T2 Biosystems to Report Fourth Quarter and Full Year 2020 Financial Results on March 4, 2021
    GlobeNewswire

    T2 Biosystems to Report Fourth Quarter and Full Year 2020 Financial Results on March 4, 2021

    LEXINGTON, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it will report financial results for the fourth quarter and full year 2020 after market close on Thursday, March 4, 2021. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com, on the Investors page in the Events & Presentations section. The call will also be available by dialing 877-407-9208 (U.S.) or 201-493-6784 (International) five to ten minutes prior to the start time. About T2 Biosystems:T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Candida® Panel, the T2Bacteria® Panel, the T2Resistance™ Panel, and the T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including the T2Cauris™ Panel, and T2Lyme™ Panel, as well as additional products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers, and biothreat pathogens. Media Contact:Gina Kent, Vault Communicationsgkent@vaultcommunications.com610-455-2763 Investor Contact:Philip Trip Taylor, Gilmartin Groupphilip@gilmartinIR.com415-937-5406

  • T2 Biosystems to Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostics Tools Conference
    GlobeNewswire

    T2 Biosystems to Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostics Tools Conference

    LEXINGTON, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that the Company plans to participate in the upcoming BTIG Virtual MedTech, Digital Health, Life Science & Diagnostics Tools Conference. Management is scheduled to present Friday, February 19, 2021 at 10:00am ET. Interested parties may access a live and recorded webcast of the presentation on the “Investors” section of the Company’s website at www.t2biosystems.com. About T2 BiosystemsT2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Candida® Panel, the T2Bacteria® Panel, the T2Resistance™ Panel, and the T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including the T2Cauris™ Panel, and T2Lyme™ Panel, as well as additional products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers, and biothreat pathogens. Media Contact:Gina Kent, Vault Communicationsgkent@vaultcommunications.com 610-455-2763 Investor Contact:Philip Trip Taylor, Gilmartin Groupphilip@gilmartinIR.com 415-937-5406

  • Why T2 Biosystems Stock Soared Today
    Motley Fool

    Why T2 Biosystems Stock Soared Today

    Shares of T2 Biosystems (NASDAQ: TTOO) jumped on Friday after the healthcare diagnostics specialist said its testing panel could detect the new strain of the coronavirus first identified in Brazil. T2 Biosystems has now confirmed that its T2SARS-CoV-2 Panel can detect many different coronavirus strains, including the variants first identified in the U.K., South Africa, and Brazil. A recent evaluation of more than 42,000 genome sequences for the novel coronavirus showed that T2 Biosystems' panel should detect 99.99% of all currently identified SARS-CoV-2 viruses.